Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, November 16, 2021
[ Tue, Nov 16th 2021
] - WOPRAI
Mon, November 15, 2021
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
[ Mon, Nov 15th 2021
] - WOPRAI
Joseph Schwartz Maintained (ASND) at Buy with Increased Target to $190 on, Nov 15th, 2021
Joseph Schwartz of SVB Leerink, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $182 to $190 on, Nov 15th, 2021.
Joseph has made no other calls on ASND in the last 4 months.
There are 3 other peers that have a rating on ASND. Out of the 3 peers that are also analyzing ASND, 1 agrees with Joseph's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold and Increased Target to $169 on, Wednesday, October 20th, 2021
These are the ratings of the 2 analyists that currently disagree with Joseph
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $179 on, Thursday, November 11th, 2021
- David Lebowitz of "Morgan Stanley" Maintained at Buy with Increased Target to $204 on, Thursday, August 26th, 2021
